Results 21 to 30 of about 320,592 (205)

Fc receptor engagement of HIV-1 Env-specific antibodies in mothers and infants predicts reduced vertical transmission

Frontiers in Immunology, 2022
IntroductionInfants acquire maternal antibodies by Fc receptor transcytosis across the placenta during pregnancy. Fc receptors are expressed on immune cells and are important for activation of effector cell functions.MethodsIn this study, we evaluated Fc
Brittani M. Barrows, Brittani M. Barrows, Brittani M. Barrows, Shelly J. Krebs, Shelly J. Krebs, Ningbo Jian, Ningbo Jian, Michelle Zemil, Michelle Zemil, Bonnie M. Slike, Bonnie M. Slike, Vincent Dussupt, Vincent Dussupt, Ursula Tran, Ursula Tran, Letzibeth Mendez-Rivera, Letzibeth Mendez-Rivera, David Chang, David Chang, Anne Marie O’Sullivan, Anne Marie O’Sullivan, Brendan Mann, Brendan Mann, Eric Sanders-Buell, Eric Sanders-Buell, Zhanna Shubin, Zhanna Shubin, Matt Creegan, Matt Creegan, Dominic Paquin-Proulx, Dominic Paquin-Proulx, Philip Ehrenberg, Philip Ehrenberg, Agnes Laurence-Chenine, Agnes Laurence-Chenine, Kriengkrai Srithanaviboonchai, Rasmi Thomas, Michael A. Eller, Michael A. Eller, Guido Ferrari, Merlin Robb, Merlin Robb, Venigalla Rao, Sodsai Tovanabutra, Sodsai Tovanabutra, Victoria R. Polonis, Lindsay Wieczorek, Lindsay Wieczorek   +47 more
doaj   +1 more source

Functional stability of HIV-1 envelope trimer affects accessibility to broadly neutralizing antibodies at its apex [PDF]

, 2017
The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer instability and heterogeneity in principle make subunit interfaces inconsistent targets for the ...
Gift, Syna Kuriakose, Kim, Arthur S, Leaman, Daniel P, Zhang, Lei, Zwick, Michael B   +4 more
core   +2 more sources

bNAber: database of broadly neutralizing HIV antibodies. [PDF]

, 2013
The discovery of broadly neutralizing antibodies (bNAbs) has provided an enormous impetus to the HIV vaccine research and to entire immunology. The bNAber database at http://bNAber.org provides open, user-friendly access to detailed data on the rapidly ...
Burton, Dennis R, Butera, Sal T, Eroshkin, Alexey M, Godzik, Adam, LeBlanc, Andrew, Li, Zhanwen, Post, Kai, Rajput, Akhil, Weekes, Dana   +8 more
core   +4 more sources

HIV broadly neutralizing antibody targets [PDF]

Current Opinion in HIV and AIDS, 2015
To provide an update on neutralizing antibody targets in the context of the recent HIV-1 envelope trimer structure, describe new antibody isolation technologies, and discuss the implications of these data for HIV-1 prevention and therapy.Recent advances in B-cell technologies have dramatically expanded the number of antibodies isolated from HIV ...
Constantinos Kurt, Wibmer, Penny L, Moore, Lynn, Morris   +2 more
openaire   +2 more sources

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. [PDF]

PLoS Medicine, 2009
The antibody response to HIV-1 does not appear in the plasma until approximately 2-5 weeks after transmission, and neutralizing antibodies to autologous HIV-1 generally do not become detectable until 12 weeks or more after transmission.
Marc C Levesque, M Anthony Moody, Kwan-Ki Hwang, Dawn J Marshall, John F Whitesides, Joshua D Amos, Thaddeus C Gurley, Sallie Allgood, Benjamin B Haynes, Nathan A Vandergrift, Steven Plonk, Daniel C Parker, Myron S Cohen, Georgia D Tomaras, Paul A Goepfert, George M Shaw, Jörn E Schmitz, Joseph J Eron, Nicholas J Shaheen, Charles B Hicks, Hua-Xin Liao, Martin Markowitz, Garnett Kelsoe, David M Margolis, Barton F Haynes   +24 more
doaj   +1 more source

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding [PDF]

, 2011
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that vaccines that elicit such antibodies would be protective.
Abadir, Alexander, Bjorkman, Pamela J., Boulad, Farid, Burton, Dennis R., Chait, Brian T., Diskin, Ron, Fenyo, David, Ho, David D., Hurley, Arlene, Klein, Florian, Mouquet, Hugo, Myung, Sunnie, Nussenzweig, Michel C., Oliveira, Thiago Y. K., Pereyra, Florencia, Pietzsch, John, Poignard, Pascal, Scheid, Johannes F., Seaman, Michael S., Ueberheide, Beatrix, Velinzon, Klara, Walker, Bruce D.   +21 more
core   +2 more sources

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.

PLoS Pathogens, 2016
Emerging data support a role for antibody Fc-mediated antiviral activity in vaccine efficacy and in the control of HIV-1 replication by broadly neutralizing antibodies.
Matthew Zirui Tay, Pinghuang Liu, LaTonya D Williams, Michael D McRaven, Sheetal Sawant, Thaddeus C Gurley, Thomas T Xu, S Moses Dennison, Hua-Xin Liao, Agnès-Laurence Chenine, S Munir Alam, M Anthony Moody, Thomas J Hope, Barton F Haynes, Georgia D Tomaras   +14 more
doaj   +1 more source

9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles. [PDF]

PLoS ONE, 2013
Potent HIV-1 specific broadly neutralizing antibodies (BNA) are uncommon in HIV infected individuals, and have proven hard to elicit by vaccination. Several, isolated monoclonal BNA are polyreactive and also recognize self-antigens, suggesting a breach ...
Danielle C Alcéna, James J Kobie, Denise A Kaminski, Alexander F Rosenberg, Jonelle L Mattiacio, Matthew Brewer, Stephen Dewhurst, Carrie Dykes, Xia Jin, Michael C Keefer, Ignacio Sanz   +10 more
doaj   +1 more source

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola, Ralph Steinman, Richter C. King, the Working Group convened by the Global HIV Vaccine Enterprise   +3 more
core   +3 more sources

Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]

, 2014
The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA, Montefiori D.C., Pabst M., Pegu A., WHO   +4 more
core   +1 more source